🔎 Trials Near Me

መነሻ › አኩት ማይሎይድ ሊውኬሚያ › ኢሊኖይ

በኢሊኖይ ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 31 ጥናቶች በኢሊኖይ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በኢሊኖይ ውስጥ ያሉ ከተሞች

Official study text (English)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • Illinois CancerCare-Carthage, Carthage
  • እና 15 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 60 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • OSF Saint Anthony's Health Center, Alton
  • Rush-Copley Medical Center, Aurora
  • Advocate Outpatient Center - Aurora, Aurora
  • እና 54 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • University of Chicago Comprehensive Cancer Center, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Centralia Oncology Clinic, Centralia
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • እና 13 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • University of Chicago Medicine, Chicago
  • Illinois Cancer Specialists, Niles
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Advocate Outpatient Center - Aurora, Aurora
  • Advocate Good Shepherd Hospital, Barrington
  • OSF Saint Joseph Medical Center, Bloomington
  • እና 54 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  • Lurie Children's Hospital-Chicago, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1
እስከ እድሜ 21 · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • እና 26 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • እና 14 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • OSF Saint Joseph Medical Center, Bloomington
  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • እና 29 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
6 Months – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • The University of Chicago Medical Center, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
30 Days · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT04065399

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

  • University of Chicago, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Lurie Children's Hospital-Chicago, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ1 እስከ 25 · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT07022678

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • City of Hope - Chicago, Zion
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT04588922

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  • US-Chigago IL-UHCHICAGO, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ሴፕቴ 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • University of Chicago Comprehensive Cancer Center, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • እና 6 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
  • Comer Children's Hospital, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 3
29 Days – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ24 ኦገስ 2026 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
  • Loyola University Medical Center, Maywood
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT06001788

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

  • Research Site, Decatur
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 16 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ጁላይ 2026 · NCT07155226

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • እና 3 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

  • University of Illinois Cancer Center, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ26 ጁን 2026 · NCT06802315

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • University of Chicago, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 13 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT04771572

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

  • Northwestern University, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ኤፕሪ 2026 · NCT05732103

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Northwestern, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ማርች 2026 · NCT04988555

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

  • Northwestern Medicine, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ማርች 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
  • Loyola University Medical Center, Maywood
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ማርች 2026 · NCT05735184

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

  • Northshore University Health System, Evanston
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ፌብሩ 2026 · NCT05974150

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2025 · NCT06501196

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • Northwestern University, Evanston
ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ18 እስከ 120 · ሁሉም ጾታዎች · የተሻሻለው በ25 ጁላይ 2025 · NCT05237258

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።